A Review of Immunotherapy for Stage III and Metastatic Non‐Small Cell Lung Cancer and the Rationale for the ECOG‐ACRIN EA5181 Study

ECOG‐ACRIN EA5181 is a phase III prospective, randomized trial that randomizes patients undergoing chemo/radiation for locally advanced non‐small cell lung cancer (LA‐NSCLC) to concomitant durvalumab or no additional therapy, with both arms receiving 1 year of consolidative durvalumab. Radiation dos...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Oncologist
मुख्य लेखकों: Varlotto, John M., Sun, Zhuoxin, Ky, Bonnie, Upshaw, Jenica, Katz, Sharyn I., Fitzgerald, Thomas J., Wakelee, Heather, Diehn, Maximilian, Mankoff, David A., Lovely, Christine, Belani, Chandra, Oettel, Kurt, Masters, Gregory, Ramalingam, Suresh, Pennell, Nathan A.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: John Wiley & Sons, Inc. 2021
विषय:
Lung Cancer
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC8176975/
https://ncbi.nlm.nih.gov/pubmed/33594771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13725
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन